Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: Final results of the DEFINITIVE Ca++ trial
Catheterization and Cardiovascular Interventions2014Vol. 84(2), pp. 236–244
Citations Over TimeTop 10% of 2014 papers
David K. Roberts, Khusrow Niazi, William E. Miller, Prakash Krishnan, Roger Gammon, Theodore Schreiber, Nicolas W. Shammas, Daniel G. Clair, on behalf of the DEFINITIVE Ca Investigators
Abstract
The results of the DEFINITIVE Ca++ study demonstrate that the SilverHawk and TurboHawk atherectomy devices are safe and effective in the endovascular treatment of moderate to severely calcified lesions in the superficial femoral and/or popliteal arteries when used with the SpiderFX distal embolic protection device.
Related Papers
- → Registry Assessment of Peripheral Interventional Devices objective performance goals for superficial femoral and popliteal artery peripheral vascular interventions(2020)8 cited
- → Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy(2017)22 cited
- → LB-3 | Clinical Outcomes of the XIENCE Skypoint 48mm Drug-Eluting Stent in Long Coronary Artery Lesions: Primary Endpoint Data from the SPIRIT 48 Trial(2023)2 cited
- → Use of the Orbital Atherectomy System in Isolated, Chronic Atherosclerotic Lesions of the Popliteal Artery(2020)2 cited
- → Outcomes of Endovascular Intervention of Atherosclerotic Lesions Confined to the Popliteal Artery(2023)